) Profit before FX per share (Baht) 5.25 4.35 0.90 Leverage Ratio and Liquidity Ratio Quarter 2 Quarter 1 Change Increase/(Decrease) 2019 2019 Debt to equity ratio (Time) - Consolidated 1.03 1.11 (0.08
Liquidity Ratio Quarter 3 2020 Quarter 2 2020 Increase/(Decrease) Debt to equity ratio (Time) - Consolidated 1.13 1.19 (0.06) - Company 0.67 0.67 - Book value per share (Baht) - Consolidated 193.42 186.06
based on a total value of consideration paid basis, calculated from the audited consolidated financial statements of the Company for the year ended 31 December 2017. In the previous 6- month period, the
were calculated based on the consolidated financial statements which consist of the Expressway Business, Rail Business, Commercial Development Business, the manufacture and distribution of treated water
Ended December 31, 2018 To The President The Stock Exchange of Thailand Management Discussion and Analysis Consolidated Financial Statements For Financial Year ended December 31, 2018 Overall Group
98.3 million Baht, this is the new revenues in consolidated financial statement. Analysis of Cost of Services and Gross Profit In 2018, the Company’s cost of services was 672.4 million Baht higher than
, Suriyawong, Bangrak, Bangkok 10500, Thailand. Tel. 02-634-0225 Fax 02-634-0135 www.interpharma.co.th Consolidated For the Year Ended December 31 2019 2018 MB % MB % Total revenues 375.89 100.00 317.58 100.00
Limited ( “ the Company” ) would like to submit this Management Discussion and Analysis for the year ended 31 December 2019 with details as follows: ( Since the consolidated financial statements included
relation to import duty assessment. งบกาํไรขาดทุนเบ็ดเสร็จ Consolidated For the Year Ended December 31 2019 2018 MB % MB % Total revenues 375.89 100.00 317.58 100.00 Cost of sales (157.39) (41.87) (125.04
relation to import duty assessment. Consolidated For the Year Ended December 31 2019 2018 MB % MB % Total revenues 375.89 100.00 317.58 100.00 Cost of sales (157.39) (41.87) (125.04) (39.77) Selling expenses